Ahmedabad, India / Valence, France, April 25, 2025
Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited (“Zydus”) and
Amplitude Surgical SA (“Amplitude”) confirm that Amplitude has conducted the mandatory
information and consultation process with the works council of Amplitude SAS. Consequently, Zydus
has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude 1 at a price
of €6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude,
which together with the two share purchase agreements already signed on March 11, 2025 with two
minority shareholders represent 85.6% of the share capital of Amplitude (the “Block Acquisition”).
As indicated in the joint announcement of March 11, 2025, the completion of the Block Acquisition
remains subject to the usual closing conditions, including authorization from the French Minister of
Economy as part of the control of foreign investments in France, the re-investment by Amplitude CEO
Olivier Jallabert into the company, as well as the absence of qualified material adverse events.
Subject to the fulfilment of the closing conditions, Zydus will acquire 85.6% of the share capital of
Amplitude.
The closing of the Block Acquisition is now expected to be completed by Q3 2025. After such
completion, Zydus’ mandatory simplified tender offer would be filed with the Autorité des Marchés
Financiers (“AMF”) and would be followed by a squeeze out if the conditions are met. The opening of
the subsequent tender offer would then remain subject to the AMF’s clearance decision.
In this respect and as announced on April 17, 2025, commitments to tender 4.7% of Amplitude’s share
capital have been executed with other minority shareholders of Amplitude. As a consequence, and
subject to the condition precedents hereabove, Zydus will be in a position to acquire more than 90 % of
the capital and voting rights of Amplitude at the end of the tender offer, and therefore to implement a
squeeze-out procedure.
Contact Information
Zydus Lifesciences Limited
Sujatha Rajesh
Media Relations
sujatha.rajesh@zyduslife.com
+91-9974051180
Arvind Bothra
Investor Relations
arvind.bothra@zyduslife.com
+91-7045656895
Brunswick
Media Relations
zydus@brunswickgroup.com
Hugues Boëton +33 6 79 99 27 15
Flora Marinho + 33 6 07 46 34 35
Amplitude Surgical
Amplitude Surgical
Chief Financial Officer
Dimitri Borchtch
finances@amplitude-surgical.com
+33 4 75 41 87 41
NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
+33 1 44 71 94 94
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 1 44 71 94 98
PAI Partners
Dania Saidam
dania.saidam@paipartners.com
+44 20 7297 4678
About Zydus Lifesciences
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live
healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers,
develops, manufactures, and markets a broad range of healthcare therapies. The group employs over
27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to
unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group
aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market
for surgical technologies for lower limb orthopaedics. Amplitude Surgical develops and markets high-
end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee.
Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added
innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France,
Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and
exclusive distributors in over 30 countries. As of June 30, 2024, Amplitude Surgical employed 428
people and generated sales of nearly €106.0 million.
